Livzon Pharmaceutical Group Inc. recently issued an announcement detailing significant changes to its Board of Directors and senior management. All relevant information is drawn directly from the disclosure, with key points summarized below.

On 28 February 2026, two directors—Mr. Xu Guoxiang and Mr. Tao Desheng—tendered their resignations upon reaching retirement age. Mr. Xu also resigned from his positions as Executive Director, Vice Chairman, and Vice President, while Mr. Tao resigned as Non-Executive Director, Vice Chairman, and member of the Board’s Nomination and Strategy Committees. Following their departures, Mr. Xu holds 0.78 million A shares in the company, and Mr. Tao holds 0.73 million A shares, with Mr. Tao’s spouse holding 0.15 million A shares. Both confirmed no disagreements with the Board.

Additionally, the announcement notes the resignation of President Mr. Tang Yanggang (who retains his directorship) and Vice President and Financial Controller Ms. Si Yanxia. Mr. Tang holds 0.34 million A shares of the company, and Ms. Si holds 0.43 million A shares. In appreciation of all four individuals, the Board acknowledged their efforts in advancing the company’s development.

The Board proposes appointing Vice President Mr. Liu Daping as an Executive Director; his formal appointment is subject to shareholder approval. Effective 28 February 2026, Mr. Liu assumes the role of President. Mr. Liu’s annual director’s fee is RMB96,000 pre-tax, with additional remuneration for his presidential role.

Executive Director Mr. Tang is newly appointed as Vice Chairman, effective 28 February 2026. His annual director’s fee is RMB3.00 million pre-tax. Meanwhile, Mr. Wang Sheng is appointed as Financial Controller, and Mr. Chen Zhihua is appointed as Vice President, both effective 28 February 2026. Mr. Wang had been serving as the Chief Financial Officer since September 2025, and Mr. Chen was previously Deputy General Manager of the Prescription Drug Business Unit.

The company also highlights a change in its authorized representative under the Hong Kong Listing Rules. This role shifts from Mr. Tang to Mr. Liu on the date Mr. Liu’s appointment as an Executive Director is approved by shareholders. The other authorized representative remains Ms. Liu Ning, the Company Secretary.

According to the announcement, as of 1 March 2026, the company’s Executive Directors are: Vice Chairman Mr. Tang; Non-Executive Directors include Chairman Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and Independent Non-Executive Directors include Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao.